SOLIRIS®- the prospect of more relapse-free days SOLIRIS® (eculizumab) is indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.1 Please refer to the SOLIRIS® Summary of Product Characteristics.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional

In patients with AQP4 antibody-positive NMOSD, uncontrolled terminal complement activation caused by auto-antibodies against AQP4 leads to the formation of the membrane attack complex (MAC) and C5a-dependent inflammation.1

This results in astrocyte necrosis and increased permeability of the blood-brain barrier, as well as death of the surrounding oligodendrocytes and neurons.1

Chronic administration of SOLIRIS® results in immediate, complete, and sustained C5 inhibition and has demonstrated the potential to address NMOSD relapses.1,2
Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following email: https://contactazmedical.astrazeneca.com/
SOLIRIS® (eculizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/ documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: December 2023. Pittock SJ, et al. Eculizumab in anti-aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. Plus Supplementary materials.